The Epigenetic Modifier PRDM5 Functions as a Tumor Suppressor through Modulating WNT/β-Catenin Signaling and Is Frequently Silenced in Multiple Tumors

• Xing-sheng Shu ,

  Contributed equally to this work with: Xing-sheng Shu, Hua Geng

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Hua Geng ,

  Contributed equally to this work with: Xing-sheng Shu, Hua Geng

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Lili Li,

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Jianming Ying,

  Affiliation Department of Pathology, Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

  ⨯
• Chunhong Ma,

  Affiliation Shandong University School of Medicine, Shandong, China

  ⨯
• Yajun Wang,

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Fan Fong Poon,

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Xian Wang,

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Ying Ying,

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Winnie Yeo,

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• Gopesh Srivastava,

  Affiliation Department of Pathology, University of Hong Kong, Hong Kong, China

  ⨯
• Sai Wah Tsao,

  Affiliation Department of Anatomy, University of Hong Kong, Hong Kong, China

  ⨯
• Jun Yu,

  Affiliation Institute of Digestive Disease and Department of Medicine, The Chinese University of Hong Kong, Hong Kong, China

  ⨯
• Joseph J. Y. Sung,

  Affiliation Institute of Digestive Disease and Department of Medicine, The Chinese University of Hong Kong, Hong Kong, China

  ⨯
• Shi Huang,

  Affiliation State Key Laboratory of Medical Genetics, Xiangya Medical School, Central South University, Changsha, China

  ⨯
• Anthony T. C. Chan,

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
•  [ ... ],
• Qian Tao

  * E-mail: qtao@clo.cuhk.edu.hk

  Affiliation Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, and CUHK Shenzhen Research Institute, Hong Kong, China

  ⨯
• [ view all ]
• [ view less ]